Cytolethal Distending Toxin-induced Cell Cycle Arrest of Lymphocytes Is Dependent upon Recognition and Binding to Cholesterol*

Received for publication, December 3, 2008, and in revised form, February 4, 2009. Published, JBC Papers in Press, February 23, 2009, DOI 10.1074/jbc.M809094200

Kathleen Boesze-Battaglia, Angela Brown, Lisa Walker, Dave Besack, Ali Zekavat, Steve Wrenn, Claude Krummenacher, and Bruce J. Shenker

From the Departments of Biochemistry and Pathology, University of Pennsylvania School of Dental Medicine, and Department of Chemical and Biological Engineering, Drexel University, Philadelphia, Pennsylvania 19104-6030

Induction of cell cycle arrest in lymphocytes after exposure to the Aggregatibacter actinomycetemcomitans cytolethal distending toxin (Cdt) is dependent upon the integrity of lipid membrane microdomains. In this study we further demonstrate that the association of Cdt with lymphocyte plasma membranes is dependent upon binding to cholesterol. Depletion of cholesterol resulted in reduced toxin binding, whereas repletion of cholesterol-depleted cells restored binding. We employed fluorescence resonance energy transfer and surface plasmon resonance to demonstrate that toxin association with model membranes is dependent upon the concentration of cholesterol; moreover, these interactions were cholesterol-specific as the toxin failed to interact with model membranes containing stigmasterol, ergosterol, or lanosterol. Further analysis of the toxin indicated that the CdtC subunit contains a cholesterol recognition/interaction amino acid consensus (CRAC) region. Mutation of the CRAC site resulted in decreased binding of the holotoxin to cholesterol-containing model membranes as well as to the surface of Jurkat cells. The mutant toxin also exhibited reduced capacity for intracellular transfer of the active toxin subunit, CdtB, as well as reduced toxicity. Collectively, these observations indicate that membrane cholesterol serves as an essential ligand for Cdt and that this association can be blocked by either depleting membranes of cholesterol or mutation of the CRAC site.

There is clear evidence that Cdts are encoded by three genes, designated cdta, cdtb, and cdtc, which are arranged as an apparent operon (7–14). These three genes specify three polypeptides designated CdtA, CdtB, and CdtC with apparent molecular masses of 28, 32 and 20 kDa, respectively. There is compelling evidence that CdtB is labile protein cytotoxins produced by several different bacterial species including diarrheal disease-causing enteropathogens such as some Escherichia coli isolates, Campylobacter jejuni, Shigella species, Haemophilus ducreyi, and Aggregatibacter (formerly Actinobacillus) actinomycetemcomitans (1–7). There is no evidence that Cdts are encoded by three genes, designated cdta, cdtb, and cdtc, which are arranged as an apparent operon (7–14). These three genes specify three polypeptides designated CdtA, CdtB, and CdtC with apparent molecular masses of 28, 32 and 20 kDa, respectively, that form a heterotrimeric holotoxin. Cdt toxicity is associated with cell cycle arrest and eventual cell death resulting from activation of the apoptotic cascade (10, 11, 15–17). Although several cell lines and cell types have been shown to be susceptible to the toxic effects of Cdt, we have previously shown that lymphocytes are the most sensitive (18). For this reason we believe that lymphocytes are a likely in vivo target of Cdt and further propose that Cdt represents a novel immunotoxin.

Considerable agreement exists among investigators that regardless of the microbial source of Cdt, the heterotrimeric holotoxin functions as an AB2 toxin where CdtB is the active (A) unit and the complex of CdtA and CdtC comprises the binding (B) unit (12, 19, 20). There is compelling evidence that CdtB must be internalized to induce cell cycle arrest (19, 21, 22). Moreover, we have recently demonstrated that the active Cdt subunit, CdtB, functions as a phosphatidylinositol 3,4,5-triphosphate phosphatase similar to that of the tumor suppressor phosphatases, PTEN and SHIP1 (23–25). We have further demonstrated that Cdt-induced G2 arrest is dependent upon its ability to function as a lipid phosphatase and most likely results from toxin induced perturbations in the Akt signaling pathway.

In previous studies we have shown that binding subunits CdtA and CdtC are not only required for the toxin to associate with cells but are necessary to localize the toxin to lipid membrane microdomains (18, 26). Furthermore, Cdt-mediated toxicity is dependent upon the integrity of these lipid domains. We now report that not only does cholesterol depletion and disruption of lipid membrane microdomains confer resistance to Cdt-induced G2 arrest, but association of the Cdt holotoxin to lymphocytes also involves cholesterol. Specifically, we have utilized both fluorescence resonance energy transfer (FRET) and surface plasmon resonance (SPR) analysis to demonstrate interaction between the CdtC subunit and cholesterol in cholesterol containing liposomes. Moreover, we have identified a cholesterol recognition/interaction amino acid consensus site (CRAC) on CdtC that is required for these interactions (27). Mutation of the CRAC site reduces interaction with lymphocyte plasma membrane and with cholesterol-containing lipo-
some and also reduces delivery of CdtB to the cell and con- 
comitant G2 arrest.

**EXPERIMENTAL PROCEDURES**

*Cell Lines and Analysis of Cell Cycle*—The human leukemic 
T cell line Jurkat was maintained in RPMI 1640 supplemented 
with 10% fetal calf serum, 2 mM glutamine, 10 mM HEPES, 100 
units/ml penicillin, and 100 µg/ml streptomycin. Cells were 
harvested in mid-logarithmic growth phase and plated at 5 × 
10⁶ cells/ml or as indicated in 24-well tissue culture plates. The 
cells were exposed to medium or Cdt and incubated for 18 h. To 
measure Cdt-induced cell cycle arrest, Jurkat cells were washed 
and fixed for 60 min with cold 80% ethanol (18). After washing, 
the cells were stained with 10 µg/ml propidium iodide contain-
ing 1 mg/ml RNase (Sigma) for 30 min. Samples were analyzed 
on a BD Biosciences Facstar®PLUS flow cytometer. Propidium 
iodide fluorescence was excited by an argon laser operating at 
488 nm, and fluorescence was measured with a 630/22-nm 
bandpass filter using linear amplification. A minimum of 
15,000 events was collected on each sample; cell cycle analysis 
was performed using ModFit (Verity Software House; Top-
sham, ME).

*Construction and Expression of CdtABC<sup>Y71P</sup> Mutant*—
Amino acid substitution was introduced into the cdtC gene by 
in vitro site-directed mutagenesis using the following oligonu-
cleotide primer pair: (forward) 5'-GGAATTAATTGAT-
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in vitro 
in v
(tryptophan) at its maximal emission wavelength (360 nm) in the presence and absence of acceptor (DAN-PC) using the equation $E(\%) = 1 - \frac{F_{DA}}{F_D}$, where $F_{DA}$ and $F_D$ are the donor emission intensities in the presence and absence of acceptor, respectively (32). Fluorescence measurements were obtained using a steady-state fluorescence spectrometer (Photon Technology International, Ontario, Canada) with a circulating water bath to maintain the sample temperature to $+0.5{^\circ}C$. The temperature was read on a cuvette thermometer (Fisher).

**Immunofluorescence and Flow Cytometry**—Jurkat cells (2 $\times$ 10^6) were incubated for 2 h in the presence of medium or 2 $\mu$g/ml of CdtABCw or CdtABCY71P at 5 °C. Cells were washed, exposed to normal mouse IgG (Zymed Laboratories Inc.; San Francisco, CA) and then stained (30 min) for cell surface CdtC peptides with anti-Cdt subunit monoclonal antibody conjugated to Alexafluor 488 (Molecular Probes; Eugene, OR) according to the manufacturer’s directions. After washing, the cells were fixed in 2% paraformaldehyde and analyzed by flow cytometry or confocal microscopy as previously described (26). Intracellular CdtB was detected after exposure of Jurkat cells to 2 $\mu$g/ml concentrations of either CdtABCw or CdtABCY71P for 60 min at 37 °C. Cells were fixed with 2% formaldehyde for 30 min, permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate, and stained with anti-CdtB monoclonal antibody conjugated to Alexafluor 488 (Molecular Probes).

**Statistical Analyses**—Data were analyzed using Sigma Stat Version 3.1. Concentration-dependent binding of toxin to sterol or sphingomyelin-containing vesicles were analyzed by Student $t$ test using a 95% confidence interval. One-way analysis of variance was used to determine whether there was a statistically significant trend in binding of toxin to liposomes or energy transfer between toxin and liposomes of various compositions.

**RESULTS**

It is generally accepted that the CdtA and CdtC subunits are required for interaction of the Cdt holotoxin with target cell membranes leading to intracellular delivery of the active subunit, CdtB, and subsequent G2 arrest. We have previously shown that after exposure to Cdt holotoxin, the individual subunits can be detected associated with Jurkat cell membranes and, in particular, with membrane lipid rafts. We have also demonstrated that Cdt association with lymphocytes is cholesterol-dependent upon the integrity of lipid membrane microdomains (26). Furthermore, we now demonstrate that the association of Cdt holotoxin with lymphocytes is cholesterol-dependent. Jurkat cell membranes were depleted of cholesterol with
Cytolethal Distending Toxin Subunit C Binds to Cholesterol

FRET was first employed to assess Cdt association with model membranes composed of varying amounts of cholesterol. For these experiments, DAN-PC was incorporated into LUVs, and energy transfer to tryptophan residues intrinsic to Cdt was measured as a function of increasing cholesterol (Fig. 2A). Energy transfer increased from 8.9% in the presence of 10% cholesterol to 21.3% in the presence of 40% cholesterol. Direct binding of Cdt to cholesterol was also measured in real-time using SPR. Cholesterol-containing LUVs were immobilized on L1 sensor chips; LUVs prepared in the absence of cholesterol were also immobilized and used as a control. Cdt holotoxin was injected, and the association of toxin with LUV was followed for 3 min. The sample was then replaced with buffer, and the dissociation of the complex was followed for another 10 min. Fig. 2B shows a group of sensorgram overlays for the binding of Cdt holotoxin to immobilized LUVs containing varying amounts of cholesterol (0–20%). Increases in binding were observed as the percentage of cholesterol in the LUV increased from 46 RU in the presence of 2.5% cholesterol (not shown) to 267 RU in the presence of 20% cholesterol. Furthermore, we observed that the amount of Cdt binding is dependent upon the concentration of toxin (Fig. 2C); significantly more toxin binding was observed in the presence of 20 μg/ml Cdt than with 10 μg/ml Cdt with LUVs containing 5–20% cholesterol. Cholesterol specificity was tested by replacing cholesterol in the LUVs with stigmasterol, ergosterol, or lanosterol. Cdt binding to the LUVs was significantly reduced when cholesterol was replaced with each of these sterols (Fig. 2D); we observed maximum RU of 937 in the presence of cholesterol compared with 179, 92, and 32 RU with lanosterol, ergosterol, and stigmasterol, respectively. These results suggest that binding is specific for cholesterol as there was no difference in the relative amount of each sterol extracted from the liposomes (see the Fig. 2 legend).

To mimic the association of toxin with lipid rafts, LUVs were prepared with lipid compositions favoring raft formation by increasing SM content from 13 to 26% in the presence of 10% cholesterol. As shown in Fig. 3, Cdt binding to LUV was measured by SPR and found to be dose-dependent; maximum RU for LUV containing 13% SM increased from 61 RU in the presence of 5 μg/ml Cdt to 522 RU in the presence of 20 μg/ml Cdt.
There was an increase in toxin binding at all toxin concentrations to LUVs containing 26% SM; at the highest toxin concentration, 20 μg/ml Cdt, we observed a 30% increase in Cdt binding, which was statistically significant. Toxin association with membrane rafts was further investigated using FRET. Energy transfer between DAN-PC and toxin increased as the mole fractions of raft-associated cholesterol increased; that is, 15.3 ± 2.2% energy transfer at 0.56 mol fraction cholesterol versus 6.2 ± 2.4% energy transfer at 0.11 mol fraction cholesterol. The SPR and FRET studies suggest that the Cdt holotoxin favors association with membrane raft-associated cholesterol.

Collectively, our results strongly support the notion that Cdt holotoxin interaction with membranes and cells is dependent upon cholesterol. Therefore, we extended our studies to consider the possibility that binding subunits, CdtA and/or CdtC, contain a cholesterol recognition motif. In this regard it has been reported that several proteins that interact with cholesterol contain an amino acid sequence known as the CRAC region. The CRAC site conforms to the pattern (L/V)X1–5-YX1–5(R/K) in which X1–5 represents between one and five residues of any amino acid (27). Motif analysis of Cdt identified a CRAC site within the CdtC subunit, 68LIDYKGK74. Location of the CRAC site in CdtC is shown in Fig. 4; this site is at the surface of the molecule and, theoretically, accessible to the membrane. To determine whether the CRAC region was required for cell surface interaction and the downstream toxic effects of Cdt, we generated a single-point mutant, CdtABCY71P. It should be noted that the tyrosine residue in this position has been shown by mutational analysis to be critical for cholesterol binding in other proteins (33). We initially employed FRET to determine whether the CdtABCY71P mutant toxin was capable of interacting with cholesterol in model membranes. As shown in Fig. 5A, CdtABCY71P compared with the wild type toxin (CdtABCwt) exhibited a significant reduction in energy transfer between DAN-PC and tryptophan residues intrinsic to the toxin at all concentrations of cholesterol employed. Although energy transfer with CdtABCwt exhibited cholesterol dose dependence, CdtABCY71P did not and is consistent with the reduced binding of the mutant toxin resulting from nonspecific interactions. Furthermore, SPR analysis indicated that the mutant toxin was unable to bind to immobilized LUVs containing cholesterol as compared with CdtABCwt (Fig. 5B); the maximum RU for CdtABCwt was 508 compared with 28 RU for the CRAC mutant.

In addition to interaction with model membranes, we employed immunofluorescence and flow cytometry to assess CdtABCY71P for its ability to interact with Jurkat cells. In Fig. 6, A–C, association of the mutant Cdt holotoxin was compared with the wild type toxin by assessing anti-CdtC fluorescence. The MCF for cells treated with CdtABCwt was 12 compared with 4.5 for control cells exposed to medium alone. The CRAC mutant exhibited a significant reduction in its ability to associate with Jurkat cells; cells treated with the CdtABCY71P exhibited a MCF of 4.4. Because it was possible that the decreased immunofluorescence resulted from reduced availability of the
epitope as opposed to decreased toxin binding, we also assessed the relative ability of the CdtABC\textsuperscript{wt} and CdtABC\textsuperscript{Y71P} to deliver CdtB intracellularly. As shown in Figs. 6, D–F, and as we have previously reported, CdtABC\textsuperscript{wt} was effective in delivering CdtB intracellularly in Jurkat cells; 1 h after exposure to 2 \(\mu\)g/ml toxin, MCF increased from 5.2 in control cells to 21.6. By comparison, the MCF was 6.9 in cells exposed to 2 \(\mu\)g/ml CdtABC\textsuperscript{Y71P}. Finally, we assessed the CRAC mutant for its ability to induce G\(_2\) arrest in Jurkat cells (Fig. 7). Sixteen hours after exposure to CdtABC\textsuperscript{wt}, we observed an increase in the percentage of G\(_2\) cells from 10.9\% (control) to 43.4\%; this compares to 11.2\% in cells similarly treated with CdtABC\textsuperscript{Y71P}.

**DISCUSSION**

*Aggregatibacter actinomycetemcomitans* Cdt holotoxin is composed of a heterotrimeric complex consisting of three distinct peptides, designated CdtA, CdtB, and CdtC. Several investigators have demonstrated that CdtB is the active subunit (18, 34–36); our own studies indicate that CdtB exhibits a unique lipid phosphatase activity whereby it de-phosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate (23). Although the role for CdtA and CdtC has been elusive, there is compelling evidence that these subunits are involved in forming a stable holotoxin complex and for recognition of cell associated receptors (12, 14, 37, 38). Indeed, our observations as well as those of other investigators support the notion that not only are CdtA and CdtC required for maximum toxin activity but also that they are involved in toxin-cell interaction (18, 26). These observations are also supported by analysis of the crystal structure of both *A. actinomycetemcomitans* and *H. ducreyi* Cdt. Nesic et al. (12) showed direct contact between CdtA-CdtB, CdtA-CdtC, and CdtB-CdtC and further that the *H. ducreyi* tripartite complex shows no signs of oligomerization. Further analysis suggests the CdtA and CdtC are both lectin-like structures, analogous to the B-chain repeats of ricin. CdtA and CdtC together form two surface elements, an aromatic cluster and a deep groove. The Cdt holotoxin structure has been confirmed for *A. actinomycetemcomitans* Cdt (37), where it has been suggested that CdtA and CdtC form the cap of a “fat stem mushroom.” These investigators further report that CdtA and CdtC have structural features similar to the lectin repeats in ricin, although they cannot be superimposed as a rigid unit over these repeats. It should also be noted that McSweeney and Dreyfus (38) have shown that *E. coli* Cdt binding to HeLa cells can be blocked by glycoproteins and fucose specific lectins but not simple sugars; these investigators proposed that Cdt binds to HeLa cells via an N-linked fucose-containing structure. These studies, however, could not discriminate between specific inhibition of binding to fucose versus steric hindrance of a distinct receptor located in the proximity of lectin and glycoprotein binding.

Our previous studies clearly indicate that the Cdt holotoxin interacts with the Jurkat cell surface and specifically associates with lipid microdomains where the Cdt subunits initially colocalize with the ganglioside, GM1. We further demonstrated that cholesterol depletion using MβCD protects cells from toxin-induced G\(_2\) arrest; thus, lipid raft integrity is necessary for the action of Cdt on target cells. In this study we also provide evidence that cholesterol depletion reduces the ability of Cdt to associate with Jurkat cells. Moreover, cholesterol repletion of MβCD-treated cells restored toxin binding to Jurkat cells to levels greater than that observed in control cells; this increase is consistent with the levels of cholesterol extracted from similarly treated cells. These results suggest that the toxin binding subunits, CdtA and/or CdtC, recognize the sterol, perhaps, in the context of lipid rafts. The possibility that Cdt interacts with cholesterol is further demonstrated by our studies in which we employed model membranes. Clearly, FRET and SPR analysis of Cdt interaction with LUVs was dependent upon the presence and concentration of cholesterol; moreover, toxin recognition of sterols was specific to cholesterol, whereas the toxin failed to bind to LUVs containing lanosterol, ergosterol, and stigmastanol. In other experiments LUVs were prepared in which the SM levels were increased from 13 to 26\% to mimic a lipid composition that favors lipid raft formation (29). These experi-
ments demonstrated an increase in Cdt binding as detected by SPR in the presence of 20% cholesterol and further suggest that Cdt binds to cholesterol under conditions where lipid raft formation is favored. These observations clearly establish that not only are lipid rafts involved in Cdt holotoxin-Jurkat cell interactions but also that toxin binding to both cell and model membranes directly involves cholesterol.

Several proteins have been shown to bind cholesterol; these include the benzodiazepine receptor, the human immunodeficiency virus transmembrane protein gp41, and caveolin (27, 33, 39, 40). Each of these cholesterol-binding proteins contain the cholesterol recognition amino acid consensus sequence (CRAC), (L/V)X₁₋₅YX₁₋₅(R/K), where X₁₋₅ represents one to five residues of any amino acid. Based upon the results from our experiments along with the effects of cholesterol depletion of lymphocytes on Cdt binding and toxicity, we analyzed both CdtA and CdtC to determine whether they also contain a CRAC motif. Motif analysis of these subunits identified a CRAC site within the CdtC subunit, 68LIDYKG74; furthermore, structural analysis of CdtC in the context of the holotoxin indicates that this site is at the surface of the molecule and, theoretically, is accessible to the membrane. Mutation of the tyrosine residue within this motif has resulted in significant reduction in Cdt binding as detected by SPR in the presence of 20% cholesterol and further suggest that Cdt binds to cholesterol under conditions where lipid raft formation is favored.

![Surface CdtC and Intracellular CdtB](image)

**FIGURE 6.** CdtABC<sup>Y71P</sup> exhibits a reduction in association with Jurkat cells as well as in its ability to deliver CdtB. Jurkat cells were exposed to medium (panels A and D), CdtABC<sup>WT</sup> (panels B and E), or CdtABC<sup>Y71P</sup> (panels C and F) for 1 h and then analyzed by immunofluorescence for the presence of surface CdtC (panels A–C) and intracellular CdtB (panels D–F). AlexaFluor fluorescence is plotted versus relative cell number. Numbers represent the mean channel fluorescence; at least 10,000 cells were analyzed per sample. Results are representative of three experiments.

![DNA Content](image)

**FIGURE 7.** CdtABC<sup>Y71P</sup> exhibits reduced ability to induce cell cycle arrest. Jurkat cells were incubated with medium alone (panel A), 50 pg/ml CdtABC<sup>WT</sup> (panel B), or 50 pg/ml CdtABC<sup>Y71P</sup> (panel C) for 18 h, stained with propidium iodide, and analyzed for cell cycle distribution by flow cytometry as described under “Experimental Procedures.” Numbers represent the percentage of cells in the G₀/G₁, S, and G₂/M phases of the cell cycle. Results are representative of three experiments; 15,000 cells were analyzed for each sample. PI, propidium iodide.
in the ability of the holotoxin to interact with LUVs. Moreover, the mutant toxin exhibited reduced binding to Jurkat cells along with a reduced intracellular transfer of CdtB and a concomitant reduction in toxicity. These observations are consistent with those of Jamin et al. (33) who mutated the same residue of the CRAC motif within the benzodiazepine receptor, which also resulted in a loss of cholesterol binding. Collectively, our results provide strong support for the notion that not only is Cdt association with target cells dependent upon the integrity of membrane lipid rafts but, furthermore, that the CdtC subunit binds to cholesterol.

Lipid rafts represent liquid-ordered microdomains that are distributed in the plasma membrane and whose lipid composition and high cholesterol content differs from the rest of the membrane. Thus, a protein such as a bacterial toxin that recognizes cholesterol would be expected to co-localize with lipid rafts; this is consistent with our observations for Cdt (26). Furthermore, association with lipid microdomains provides several advantages for proteins in general and bacterial toxins in particular because these membrane regions serve several functions including triggering internalization and transport of extracellular proteins as well as signaling platforms (41, 42). Moreover, it has become increasingly evident that several pathogens and microbial-derived toxins interact with their target cell via membrane rafts (43, 44). For instance, rafts may provide a mechanism by which receptors are concentrated and thereby promote ligand or pathogen binding. One such example is cholera toxin, which is pentameric and binds to target cells via the ganglioside GM1. It is likely that cholera toxin simultaneously binds with high affinity to multiple receptors as result of receptor concentration within the raft (44, 45). Likewise, pore-forming toxins such as aerolysin from Aeromonas hydrophila, which binds to glycosylphosphatidylinositol-anchored proteins, utilize the concentrating properties of rafts to facilitate oligomerization, a requisite for channel formation (44, 46). Membrane rafts may also facilitate signaling after the binding of bacterial toxins to raft-associated receptors. In this regard, bacterial lipopolysaccharide (LPS) interacts with rafts via CD14, a glycosylphosphatidylinositol-anchored receptor; LPS binding results in mitogen-activated protein kinase activation and eventually cytokine production. Finally, membrane rafts may serve as entry sites for pathogens; in this regard several pathogens enter host cells in a cholesterol-dependent manner (43, 44). For example, the uptake of E. coli strains which express FimH have been shown to involve cholesterol-rich rafts. Similarly, Shigella invades cells via interaction between the invasin, IpaB, and the raft-associated receptor, CD44 (47). Several enveloped and non-enveloped viruses (for example, SV40, human immunodeficiency virus, and herpes simplex virus) also require lipid rafts for binding or entry by endocytosis (48, 49).

In conclusion, we propose that binding of cholesterol by the CRAC region contained in the CdtC subunit results in the association of the Cdt holotoxin with membrane lipid rafts. It is likely that lipid raft association is critical for the internalization of the active subunit, CdtB, leading to cell cycle arrest and eventual cell death. These studies predict that cholesterol disposition within the membrane influences binding of CdtC to the cell surface; therefore, we propose that CdtC favors raft-associated cholesterol, resulting in localized toxin-rich regions. This association may also be critical to the mode of action of the toxin, thereby allowing it to hijack lipid raft-associated signaling platform(s) and perhaps provide access to pools of inositol 1,4,5-triphosphate. Although these studies do not exclude the possibility of the existence of a second receptor that might be recognized by CdtA, they do clearly demonstrate that disruption of cholesterol binding by either cholesterol depletion or mutation of the CRAC region is sufficient to block Cdt-mediated toxicity in lymphocytes.

Acknowledgment—We thank the School of Dental Medicine Flow Cytometry Core Facility for technical expertise and support of this study.

REFERENCES
29. Hekman, M., Hamm, H., Villar, A., Bader, B., Kuhlmann, J., Nickel, J., and
Cytolethal Distending Toxin Subunit C Binds to Cholesterol

Cytolethal Distending Toxin-induced Cell Cycle Arrest of Lymphocytes Is Dependent upon Recognition and Binding to Cholesterol
Kathleen Boesze-Battaglia, Angela Brown, Lisa Walker, Dave Besack, Ali Zekavat, Steve Wrenn, Claude Krummenacher and Bruce J. Shenker

doi: 10.1074/jbc.M809094200 originally published online February 23, 2009

Access the most updated version of this article at doi: 10.1074/jbc.M809094200

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 48 references, 24 of which can be accessed free at http://www.jbc.org/content/284/16/10650.full.html#ref-list-1